TALIMOGENE LAHERPAREPVEC

Known as: JS1 34.5-hGMCSF 47- pA-, T-VEC, ICP34.5-, ICP47-deleted Herpes Simplex Virus 1 (HSV-1) Incorporating the Human GM-CSF Gene 
An ICP34.5, ICP47-deleted, oncolytic herpes simplex type-1 virus (HSV-1) based on the JS1 strain, and encoding the immunostimulating factor human… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1996-2018
0204019962018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Oncolytic viruses represent a novel drug class in which native or modified viruses mediate tumor regression through selective… (More)
Is this relevant?
2017
2017
61-year-old woman with stage IIIa (T3a N1a M0) left lower leg melanoma with lesions suggestive of in-transit metastases 8 months… (More)
Is this relevant?
2016
2016
Talimogene laherparepvec (Imlygic™) is an oncolytic viral therapy that is being developed by BioVex (a subsidiary of Amgen) for… (More)
Is this relevant?
Highly Cited
2016
Highly Cited
2016
PURPOSE Combining immunotherapeutic agents with different mechanisms of action may enhance efficacy. We describe the safety and… (More)
Is this relevant?
2016
2016
Talimogene laherparepvec (T-VEC) is an oncolytic immunotherapy designed to induce tumor regression of injected lesions through… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2016
2016
BACKGROUND We previously reported that talimogene laherparepvec, an oncolytic herpes virus encoding granulocyte-macrophage colony… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2015
Highly Cited
2015
PURPOSE Talimogene laherparepvec (T-VEC) is a herpes simplex virus type 1-derived oncolytic immunotherapy designed to selectively… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Review
2015
Review
2015
Melanoma often spreads to cutaneous or subcutaneous sites that are amenable to direct, intralesional injection. As such… (More)
  • figure 1
  • table 1
Is this relevant?
Review
2015
Review
2015
Talimogene laherparepvec (T-VEC) is the first-in-class oncolytic virus immunotherapy for the treatment of cancer and was… (More)
Is this relevant?
1998
1998
This paper provides the basis for integrating the Software Cost Reduction (SCR) specification method with the T-VEC (Test VECtor… (More)
  • figure 1
  • table 7
  • table 1
  • table 8
  • table 9
Is this relevant?